CHPA today applauds the U.S. Food and Drug Administration for enforcing existing provisions in the Federal Food, Drug, and Cosmetic Act by sending warning letters to 15 companies illegally marketing cannabidiol products.
CHPA submitted this citizen petition to address the definition of a dietary supplement under section 201(ff) of the Federal Food, Drug and Cosmetic Act and to request that FDA establishes a regulatory pathway to legally market dietary supplements containing CBD.
Today CHPA submitted a citizen petition to the U.S. Food and Drug Administration urging the agency to exercise its existing statutory authority to swiftly issue regulations that establish a clear pathway for manufacturers to lawfully market cannabidiol in dietary supplements.
This week, the four leading trade associations representing the U.S. dietary supplement industry joined forces to urge Congress to take action to ensure consumer safety and provide legal clarity in the CBD product marketplace.
As many dietary supplement products are being marketed as containing cannabidiol (CBD), CHPA has an interest in this subject and we presented oral comments at FDA’s May 31, 2019, public hearing. These written comments supplement our oral remarks.